Glonghui, September 22 | Morgan Stanley released a report stating that after Dongyangguang Changjiang Pharmaceutical announced its results for the first half year, the profit forecast was raised to reflect higher operating profit margins, and the target price was raised from HK$12.5 to HK$12.6, maintaining an “gain” rating. Damo raised its 2023-2024 earnings forecast per share by 9.7% and 4.7%, respectively, to $1.7 and $1.78.
大行评级｜大摩：上调东阳光药目标价至12.6港元 维持“增持”评级
Big Bank Rating | Damo: Raise Dongyang Pharmaceutical's target price to HK$12.6 to maintain “gain” rating
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.